Unknown

Dataset Information

0

Pathologic and gene expression comparison of CT- screen detected and routinely detected stage I/0 lung adenocarcinoma in NCCN risk-matched cohorts.


ABSTRACT:

Introduction

Although three randomized control trials have proven mortality benefit of CT lung cancer screening (CTLS), <5% of eligible US smokers are screened. Some attribute this to fear of harm conveyed at shared decision visits, including the harm of overdiagnosis/overtreatment of indolent BAC-like adenocarcinoma.

Methods

Since the frequency of indolent cancers has not been compared between CTLS and routinely detected cohorts, we compare pathology and RNA expression of 86 NCCN high-risk CTLS subjects to 83 high-risk (HR-R) and 51 low-risk (LR-R) routinely detected patients. Indolent adenocarcinoma was defined as previously described for low malignant potential (LMP) adenocarcinoma along with AIS/MIA. Exome RNA sequencing was performed on a subset of high-risk (CTLS and HR-R) FFPE tumor samples.

Results

Indolent adenocarcinoma (AIS, MIA, and LMP) showed 100% disease-specific survival (DSS) with similar frequency in CTLS (18%) and HR-R (20%) which were comparatively lower than LR-R (33%). Despite this observation, CTLS exhibited intermediate DSS between HR-R and LR-R (5-year DSS: 88% CTLS, 82% HR-R, & 95% LR-R, p = 0.047), possibly reflecting a 0.4 cm smaller median tumor size and lower frequency of tumor necrosis compared to HR-R. WGCNA gene modules derived from TCGA lung adenocarcinoma correlated with aggressive histologic patterns, mitotic activity, and tumor invasive features, but no significant differential expression between CTLS and HR-R was observed.

Conclusion

CTLS subjects are at no greater risk of overdiagnosis from indolent adenocarcinoma (AIS, MIA, and LMP) than risk-matched patients whose cancers are discovered in routine clinical practice. Improved outcomes likely reflect detection and treatment at smaller size.

SUBMITTER: Burks EJ 

PROVIDER: S-EPMC8713084 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pathologic and gene expression comparison of CT- screen detected and routinely detected stage I/0 lung adenocarcinoma in NCCN risk-matched cohorts.

Burks Eric J EJ   Zhang Jiarui J   Sullivan Travis B TB   Shi Xingyi X   Sands Jacob M JM   Regis Shawn M SM   McKee Brady J BJ   McKee Andrea B AB   Zhang Sherry S   Liu Hanqiao H   Liu Gang G   Spira Avrum A   Beane Jennifer J   Lenburg Marc E ME   Rieger-Christ Kimberly M KM  

Cancer treatment and research communications 20211110


<h4>Introduction</h4>Although three randomized control trials have proven mortality benefit of CT lung cancer screening (CTLS), <5% of eligible US smokers are screened. Some attribute this to fear of harm conveyed at shared decision visits, including the harm of overdiagnosis/overtreatment of indolent BAC-like adenocarcinoma.<h4>Methods</h4>Since the frequency of indolent cancers has not been compared between CTLS and routinely detected cohorts, we compare pathology and RNA expression of 86 NCCN  ...[more]

Similar Datasets

| S-EPMC4228753 | biostudies-literature
| S-EPMC5101282 | biostudies-literature
| S-EPMC4260027 | biostudies-other
| S-EPMC3262038 | biostudies-literature
| S-EPMC5352175 | biostudies-literature
| S-EPMC11583000 | biostudies-literature
| S-EPMC6583019 | biostudies-literature
| S-EPMC5581139 | biostudies-literature
| S-EPMC11609877 | biostudies-literature
| S-EPMC7749371 | biostudies-literature